EU MDR 2026: EUDAMED, Classification & Compliance Priorities
For medical-device manufacturers, 2026 brings practical regulatory changes that should be translated into clear actions across quality, regulatory and operational teams.
EUDAMED has moved into mandatory use
A significant EU medical-device compliance milestone took effect on 28 May 2026. The European Commission made the first four EUDAMED modules mandatory: Actor Registration; UDI/Device Registration; Notified Bodies & Certificates; and Market Surveillance. This changes EUDAMED from a largely voluntary preparation activity into a core operational compliance requirement for relevant economic operators.
Why this matters
EUDAMED is designed to improve transparency, traceability and coordination across the European medical-device system. Manufacturers now need reliable processes for maintaining accurate actor and device data, ensuring appropriate UDI information, supporting certificate data flows and responding to market-surveillance requirements.
Device data and UDI readiness
Manufacturers placing devices on the EU market should confirm that required UDI/device information is correctly prepared and entered into EUDAMED. Data governance is important: product names, Basic UDI-DI relationships, identifiers, certificates and other regulatory information should be consistent across technical documentation, labels, declarations and database records.
Classification and regulatory strategy remain critical
EUDAMED implementation does not replace the broader MDR obligations. Manufacturers should continue to verify device classification, conformity-assessment routes, clinical-evaluation evidence, post-market surveillance, vigilance, technical documentation and economic-operator responsibilities. Classification decisions should be justified and documented because they influence the regulatory pathway and evidence requirements.
Practical priorities for 2026
Organizations should assign clear EUDAMED ownership, validate actor and device master data, establish change-control rules for database updates, reconcile certificates and UDI information, review internal procedures for mandatory module use, train regulatory and quality teams, and maintain readiness for authority or notified-body questions. Companies with large portfolios should consider a structured data-remediation exercise rather than handling registrations reactively.
Build compliance into normal operations
EUDAMED should be treated as part of the product lifecycle rather than a one-time registration task. Connecting database maintenance to regulatory change control, labeling, certification and post-market processes will help reduce inconsistent data and late updates.